1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Influenza Diagnostics Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Influenza Diagnostics Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Disease Epidemiology
5.2. Reimbursement Scenario
5.3. COVID-19 Pandemic Impact on Industry
6. Global Influenza Diagnostics Market Analysis and Forecast, by Flu Virus Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Flu Virus Type, 2017–2031
6.3.1. Type A
6.3.2. Type B
6.4. Market Attractiveness Analysis, by Flu Virus Type
7. Global Influenza Diagnostics Market Analysis and Forecast, by Test Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Test Type, 2017–2031
7.3.1. RT-PCR Tests
7.3.2. Rapid Influenza Diagnostic Tests (RIDTs)
7.3.3. Viral Culture
7.3.4. Immunofluorescence Assays
7.3.5. Serological Tests
7.3.6. Others (LAMP, SAMBA, etc.)
7.4. Market Attractiveness Analysis, by Test Type
8. Global Influenza Diagnostics Market Analysis and Forecast, by Product Type
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Product Type, 2017–2031
8.3.1. Kits & Reagents
8.3.2. Instrument
8.3.3. Others
8.4. Market Attractiveness Analysis, by Product Type
9. Global Influenza Diagnostics Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by End-user, 2017–2031
9.3.1. Hospitals
9.3.2. Diagnostic Centers
9.3.3. Others (academics & research institutes, etc.)
9.4. Market Attractiveness Analysis, by End-user
10. Global Influenza Diagnostics Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region
11. North America Influenza Diagnostics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Flu Virus Type, 2017–2031
11.2.1. Type A
11.2.2. Type B
11.3. Market Value Forecast, by Test Type, 2017–2031
11.3.1. RT-PCR Tests
11.3.2. Rapid Influenza Diagnostic Tests (RIDTs)
11.3.3. Viral Culture
11.3.4. Immunofluorescence Assays
11.3.5. Serological Tests
11.3.6. Others (LAMP, SAMBA, etc.)
11.4. Market Value Forecast, by Product Type, 2017–2031
11.4.1. Kits & Reagents
11.4.2. Instrument
11.4.3. Others
11.5. Market Value Forecast, by End-user, 2017–2031
11.5.1. Hospitals
11.5.2. Diagnostic Centers
11.5.3. Others (academics & research institutes, etc.)
11.6. Market Value Forecast, by Country, 2017–2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Flu Virus Type
11.7.2. By Test Type
11.7.3. By Product Type
11.7.4. By End-user
11.7.5. By Country
12. Europe Influenza Diagnostics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Flu Virus Type, 2017–2031
12.2.1. Type A
12.2.2. Type B
12.3. Market Value Forecast, by Test Type, 2017–2031
12.3.1. RT-PCR Tests
12.3.2. Rapid Influenza Diagnostic Tests (RIDTs)
12.3.3. Viral Culture
12.3.4. Immunofluorescence Assays
12.3.5. Serological Tests
12.3.6. Others (LAMP, SAMBA, etc.)
12.4. Market Value Forecast, by Product Type, 2017–2031
12.4.1. Kits & Reagents
12.4.2. Instrument
12.4.3. Others
12.5. Market Value Forecast, by End-user, 2017–2031
12.5.1. Hospitals
12.5.2. Diagnostic Centers
12.5.3. Others (academics & research institutes, etc.)
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Flu Virus Type
12.7.2. By Test Type
12.7.3. By Product Type
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Influenza Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Flu Virus Type, 2017–2031
13.2.1. Type A
13.2.2. Type B
13.3. Market Value Forecast, by Test Type, 2017–2031
13.3.1. RT-PCR Tests
13.3.2. Rapid Influenza Diagnostic Tests (RIDTs)
13.3.3. Viral Culture
13.3.4. Immunofluorescence Assays
13.3.5. Serological Tests
13.3.6. Others (LAMP, SAMBA, etc.)
13.4. Market Value Forecast, by Product Type, 2017–2031
13.4.1. Kits & Reagents
13.4.2. Instrument
13.4.3. Others
13.5. Market Value Forecast, by End-user, 2017–2031
13.5.1. Hospitals
13.5.2. Diagnostic Centers
13.5.3. Others (academics & research institutes, etc.)
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Flu Virus Type
13.7.2. By Test Type
13.7.3. By Product Type
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Influenza Diagnostics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Flu Virus Type, 2017–2031
14.2.1. Type A
14.2.2. Type B
14.3. Market Value Forecast, by Test Type, 2017–2031
14.3.1. RT-PCR Tests
14.3.2. Rapid Influenza Diagnostic Tests (RIDTs)
14.3.3. Viral Culture
14.3.4. Immunofluorescence Assays
14.3.5. Serological Tests
14.3.6. Others (LAMP, SAMBA, etc.)
14.4. Market Value Forecast, by Product Type, 2017–2031
14.4.1. Kits & Reagents
14.4.2. Instrument
14.4.3. Others
14.5. Market Value Forecast, by End-user, 2017–2031
14.5.1. Hospitals
14.5.2. Diagnostic Centers
14.5.3. Others (academics & research institutes, etc.)
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Flu Virus Type
14.7.2. By Test Type
14.7.3. By Product Type
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Influenza Diagnostics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Flu Virus Type, 2017–2031
15.2.1. Type A
15.2.2. Type B
15.3. Market Value Forecast, by Test Type, 2017–2031
15.3.1. RT-PCR Tests
15.3.2. Rapid Influenza Diagnostic Tests (RIDTs)
15.3.3. Viral Culture
15.3.4. Immunofluorescence Assays
15.3.5. Serological Tests
15.3.6. Others (LAMP, SAMBA, etc.)
15.4. Market Value Forecast, by Product Type, 2017–2031
15.4.1. Kits & Reagents
15.4.2. Instrument
15.4.3. Others
15.5. Market Value Forecast, by End-user, 2017–2031
15.5.1. Hospitals
15.5.2. Diagnostic Centers
15.5.3. Others (academics & research institutes, etc.)
15.6. Market Value Forecast, by Country/Sub-region, 2017–2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Flu Virus Type
15.7.2. By Test Type
15.7.3. By Product Type
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (by tier and size of companies)
16.2. Market Share Analysis, by Company (2022)
16.3. Company Profiles
16.3.1. 3M
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Abbott
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. F. Hoffmann-La Roche Ltd.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Becton, Dickinson and Company
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. BIOMÉRIEUX
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Bio-Rad Laboratories, Inc.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Goldsite Diagnostics Inc.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Hologic, Inc.
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. DiaSorin S.p.A.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Meridian Bioscience, Inc.
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
16.3.11. QuidelOrtho Corporation
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Product Portfolio
16.3.11.3. Financial Overview
16.3.11.4. SWOT Analysis
16.3.11.5. Strategic Overview
16.3.12. SA Scientific Ltd.
16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.12.2. Product Portfolio
16.3.12.3. Financial Overview
16.3.12.4. SWOT Analysis
16.3.12.5. Strategic Overview
16.3.13. Sekisui Diagnostics
16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.13.2. Product Portfolio
16.3.13.3. Financial Overview
16.3.13.4. SWOT Analysis
16.3.13.5. Strategic Overview
16.3.14. Siemens Healthineers
16.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.14.2. Product Portfolio
16.3.14.3. Financial Overview
16.3.14.4. SWOT Analysis
16.3.14.5. Strategic Overview
16.3.15. Thermo Fisher Scientific
16.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.15.2. Product Portfolio
16.3.15.3. Financial Overview
16.3.15.4. SWOT Analysis
16.3.15.5. Strategic Overview
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/